Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Richard S. Geary sold 8,268 shares of Ionis Pharmaceuticals stock in a transaction on Friday, October 13th. The stock was sold at an average price of $60.00, for a total transaction of $496,080.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded up 4.42% during midday trading on Tuesday, reaching $63.85. 1,988,822 shares of the company’s stock traded hands. The stock has a market cap of $7.94 billion, a P/E ratio of 306.97 and a beta of 3.12. The company’s 50-day moving average price is $54.75 and its 200-day moving average price is $49.79. Ionis Pharmaceuticals, Inc. has a 52-week low of $24.58 and a 52-week high of $64.19.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its earnings results on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a return on equity of 15.52% and a net margin of 5.25%. The company had revenue of $104.15 million during the quarter, compared to analysts’ expectations of $93.29 million. During the same period in the prior year, the business posted ($0.47) earnings per share. The company’s revenue for the quarter was up 170.7% on a year-over-year basis. On average, equities analysts predict that Ionis Pharmaceuticals, Inc. will post ($0.16) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $496,080.00 in Stock” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/17/ionis-pharmaceuticals-inc-ions-svp-sells-496080-00-in-stock.html.

Several large investors have recently bought and sold shares of the company. Hanseatic Management Services Inc. lifted its position in shares of Ionis Pharmaceuticals by 1.2% in the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after purchasing an additional 41 shares during the period. Teacher Retirement System of Texas lifted its position in shares of Ionis Pharmaceuticals by 0.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 9,673 shares of the company’s stock worth $492,000 after purchasing an additional 43 shares during the period. Public Employees Retirement Association of Colorado lifted its position in shares of Ionis Pharmaceuticals by 0.3% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 24,390 shares of the company’s stock worth $1,241,000 after purchasing an additional 65 shares during the period. Utah Retirement Systems lifted its position in shares of Ionis Pharmaceuticals by 0.5% in the 1st quarter. Utah Retirement Systems now owns 22,000 shares of the company’s stock worth $884,000 after purchasing an additional 100 shares during the period. Finally, World Asset Management Inc lifted its position in shares of Ionis Pharmaceuticals by 3.4% in the 2nd quarter. World Asset Management Inc now owns 5,614 shares of the company’s stock worth $286,000 after purchasing an additional 187 shares during the period. 89.24% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently weighed in on IONS. Needham & Company LLC reissued a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a research note on Tuesday. Jefferies Group LLC reissued an “underperform” rating and set a $18.00 target price (up previously from $17.00) on shares of Ionis Pharmaceuticals in a research note on Thursday, August 10th. Laidlaw reissued a “buy” rating and set a $65.00 target price on shares of Ionis Pharmaceuticals in a research note on Monday, August 14th. BMO Capital Markets lifted their target price on shares of Ionis Pharmaceuticals from $67.00 to $69.00 and gave the stock an “outperform” rating in a research note on Monday, August 14th. Finally, Sanford C. Bernstein began coverage on shares of Ionis Pharmaceuticals in a research note on Thursday, July 27th. They set a “market perform” rating and a $57.00 target price for the company. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $50.04.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.